在2型糖尿病患者的左心室透静功能上纤维酸的作用:一个试点研究
Kaoru Yamamoto1, Yasuharu Ohta1,2, Akihiko Taguchi1
1Department of Endocrinology, Metabolism, Hematological Science and Therapeutics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi Japan.
Diabetology international
|October 2, 2023
概括
在患有2型糖尿病和高甘油三血症的患者中,Pemafibrate改善了透析功能. 这种选择性PPARα调节器可以通过增强心脏能量代谢来预防早期糖尿病心肌病.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病心肌病症 (DCM) 是2型糖尿病 (T2D) 中透支功能障碍的主要原因.
- 变化的能量基质利用和脂毒性有助于DCM的病原性.
- 过氧体增殖器激活受体α (PPARα) 在脂毒性心肌病症中起着关键作用.
研究的目的:
- 调查选择性PPARα调节器 (SPPARMα) 纤维酸对T2D患者心脏扩张功能的影响.
- 评估pemafibrate对扩张功能关键心声学参数的影响.
主要方法:
- 一组14名患有T2D和高甘油三血症的患者接受了8至16周的佩马菲布拉特 (0.2毫克/天).
- 使用心声回声仪评估透静功能,测量早期透静填充速度 (E),晚期心房填充速度 (A),E/A比率,以及早期透静环状速度 (e') 的峰值.
- 主要终点包括从基线对E/A,e和E/e的变化.
主要成果:
- 纤维酸显著增加了平均e' (p=0.019) 和降低了E/e' (p=0.041).
- 在e'的改善与禁食血糖的增加相关 (r=0.607,p=0.021) 和非化脂肪酸水平 (r=0.592,p=0.026).
结论:
- 在2型糖尿病和高甘油三血症患者中,纤维酸治疗改善了透静功能.
- 通过pemafibrate激活PPARα可能提供一种治疗策略,以预防早期的DCM.
相关概念视频
01:29Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
01:22Heart Failure Drugs: β-Blockers
357
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
357
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12